Ponnazhagan S - Search Results

1

Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus.

Pereboeva L, Komarova S, Roth J, Ponnazhagan S, Curiel DT. Pereboeva L, et al. Among authors: ponnazhagan s. Gene Ther. 2007 Apr;14(8):627-37. doi: 10.1038/sj.gt.3302916. Epub 2007 Jan 25. Gene Ther. 2007. PMID: 17251987 Free PMC article.

2

Adeno-associated virus for cancer gene therapy.

Ponnazhagan S, Curiel DT, Shaw DR, Alvarez RD, Siegal GP. Ponnazhagan S, et al. Cancer Res. 2001 Sep 1;61(17):6313-21. Cancer Res. 2001. PMID: 11522617 Review. No abstract available.

3

Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy.

Ponnazhagan S, Mahendra G, Curiel DT, Shaw DR. Ponnazhagan S, et al. J Virol. 2001 Oct;75(19):9493-501. doi: 10.1128/JVI.75.19.9493-9501.2001. J Virol. 2001. PMID: 11533211 Free PMC article.

4

Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands.

Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M Jr. Ponnazhagan S, et al. J Virol. 2002 Dec;76(24):12900-7. doi: 10.1128/jvi.76.24.12900-12907.2002. J Virol. 2002. PMID: 12438615 Free PMC article.

5

Parvovirus vectors for cancer gene therapy.

Ponnazhagan S. Ponnazhagan S. Expert Opin Biol Ther. 2004 Jan;4(1):53-64. doi: 10.1517/14712598.4.1.53. Expert Opin Biol Ther. 2004. PMID: 14680468 Review.

6

Delivery of DNA to tumor cells in vivo using adeno-associated virus.

Ponnazhagan S, Hoover F. Ponnazhagan S, et al. Methods Mol Biol. 2004;246:237-43. doi: 10.1385/1-59259-650-9:237. Methods Mol Biol. 2004. PMID: 14970597

7

Augmentation of antitumor activity of a recombinant adeno-associated virus carcinoembryonic antigen vaccine with plasmid adjuvant.

Ponnazhagan S, Mahendra G, Lima J, Aldrich WA, Jenkins CB, Ren C, Kumar S, Kallman L, Strong TV, Shaw DR, Triozzi PL. Ponnazhagan S, et al. Hum Gene Ther. 2004 Sep;15(9):856-64. doi: 10.1089/hum.2004.15.856. Hum Gene Ther. 2004. PMID: 15353040

8

Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.

Mahendra G, Kumar S, Isayeva T, Mahasreshti PJ, Curiel DT, Stockardt CR, Grizzle WE, Alapati V, Singh R, Siegal GP, Meleth S, Ponnazhagan S. Mahendra G, et al. Among authors: ponnazhagan s. Cancer Gene Ther. 2005 Jan;12(1):26-34. doi: 10.1038/sj.cgt.7700754. Cancer Gene Ther. 2005. PMID: 15359287

9

Gene therapy for osteoinduction.

Kumar S, Ponnazhagan S. Kumar S, et al. Among authors: ponnazhagan s. Curr Gene Ther. 2004 Sep;4(3):287-96. doi: 10.2174/1566523043346219. Curr Gene Ther. 2004. PMID: 15384942 Review.

10

Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy.

Kumar S, Mahendra G, Nagy TR, Ponnazhagan S. Kumar S, et al. Among authors: ponnazhagan s. Hum Gene Ther. 2004 Dec;15(12):1197-206. doi: 10.1089/hum.2004.15.1197. Hum Gene Ther. 2004. PMID: 15684696

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

120 results

Search Page

Filters